DK2076501T3 - Krystallinske former af 3-[5-(2-fluorphenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre - Google Patents
Krystallinske former af 3-[5-(2-fluorphenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre Download PDFInfo
- Publication number
- DK2076501T3 DK2076501T3 DK07838770.1T DK07838770T DK2076501T3 DK 2076501 T3 DK2076501 T3 DK 2076501T3 DK 07838770 T DK07838770 T DK 07838770T DK 2076501 T3 DK2076501 T3 DK 2076501T3
- Authority
- DK
- Denmark
- Prior art keywords
- oxadiazol
- fluorophenyl
- benzoic acid
- crystalline forms
- crystalline
- Prior art date
Links
- OOUGLTULBSNHNF-UHFFFAOYSA-N 3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid Chemical compound OC(=O)C1=CC=CC(C=2N=C(ON=2)C=2C(=CC=CC=2)F)=C1 OOUGLTULBSNHNF-UHFFFAOYSA-N 0.000 title 1
- SRMHHEPXZLWKOK-UHFFFAOYSA-N CCCCC(CC)N Chemical compound CCCCC(CC)N SRMHHEPXZLWKOK-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84732606P | 2006-09-25 | 2006-09-25 | |
| PCT/US2007/020633 WO2008039431A2 (en) | 2006-09-25 | 2007-09-24 | Crystalline forms of 3-[5-(2-fhjorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2076501T3 true DK2076501T3 (da) | 2016-02-29 |
Family
ID=39123850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07838770.1T DK2076501T3 (da) | 2006-09-25 | 2007-09-24 | Krystallinske former af 3-[5-(2-fluorphenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre |
Country Status (29)
| Country | Link |
|---|---|
| US (10) | US7863456B2 (enExample) |
| EP (2) | EP2076501B8 (enExample) |
| JP (6) | JP5714228B2 (enExample) |
| KR (1) | KR101430144B1 (enExample) |
| CN (3) | CN102382075B (enExample) |
| AR (2) | AR062963A1 (enExample) |
| AU (1) | AU2007300542B2 (enExample) |
| BR (1) | BRPI0717107A2 (enExample) |
| CA (1) | CA2663574C (enExample) |
| CL (1) | CL2007002743A1 (enExample) |
| DK (1) | DK2076501T3 (enExample) |
| ES (2) | ES2655338T3 (enExample) |
| HK (1) | HK1207070A1 (enExample) |
| HU (1) | HUE028503T2 (enExample) |
| IL (1) | IL197717A (enExample) |
| LT (1) | LTC2076501I2 (enExample) |
| MX (2) | MX344418B (enExample) |
| MY (1) | MY191209A (enExample) |
| NO (1) | NO341858B1 (enExample) |
| NZ (1) | NZ575795A (enExample) |
| PE (3) | PE20120768A1 (enExample) |
| PL (2) | PL2076501T3 (enExample) |
| PT (1) | PT2076501E (enExample) |
| SG (2) | SG185979A1 (enExample) |
| SI (1) | SI2076501T1 (enExample) |
| TW (2) | TWI452038B (enExample) |
| UA (1) | UA99600C2 (enExample) |
| WO (1) | WO2008039431A2 (enExample) |
| ZA (1) | ZA200901949B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3549936T3 (da) | 2003-04-11 | 2021-07-12 | Ptc Therapeutics Inc | 1,2,4-oxadiazol-benzoesyreforbindelse og dens anvendelse til nonsense-undertrykkelse og behandlingen af sygdom |
| ES2683359T3 (es) * | 2005-04-08 | 2018-09-26 | Ptc Therapeutics, Inc. | Composiciones que comprenden un 1,2,4-oxadiazol y usos de las mismas para tratar enfermedades asociadas con un codón de parada prematura |
| RU2462246C2 (ru) * | 2006-03-30 | 2012-09-27 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Способы получения функционального белка из днк, имеющей нонсенс-мутацию, и лечения нарушений, ассоциированных с ней |
| PL2076501T3 (pl) * | 2006-09-25 | 2016-06-30 | Ptc Therapeutics Inc | Postacie krystaliczne kwasu 3-[5-(2-fluorofenylo)[1,2,4]oksadiazol-3-ilo]-benzoesowego |
| ES2538359T3 (es) | 2006-10-12 | 2015-06-19 | Ptc Therapeutics, Inc. | Métodos para administrar un 1,2,4-oxadiazol activo por vía oral para terapia de supresión de mutación sin sentido |
| KR101713453B1 (ko) | 2010-03-12 | 2017-03-07 | 오메로스 코포레이션 | Pde10 억제제 및 관련 조성물 및 방법 |
| WO2014153643A1 (en) * | 2013-03-26 | 2014-10-02 | The University Of British Columbia | Compositions and methods for use thereof in the treatment of aniridia |
| CN105324467B (zh) | 2013-04-03 | 2018-03-20 | Gfo油有限责任公司 | 从有机种子油产生乙醛的方法和系统 |
| DK3363790T3 (da) | 2013-09-06 | 2020-04-27 | Aurigene Discovery Tech Ltd | 1,2,4-oxadiazolderivater som immunmodulatorer |
| CA3174516A1 (en) | 2014-03-06 | 2015-09-11 | Ptc Therapeutics, Inc. | Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid |
| NZ630810A (en) | 2014-04-28 | 2016-03-31 | Omeros Corp | Processes and intermediates for the preparation of a pde10 inhibitor |
| NZ716462A (en) * | 2014-04-28 | 2017-11-24 | Omeros Corp | Optically active pde10 inhibitor |
| KR101703137B1 (ko) | 2014-05-30 | 2017-02-07 | 선문대학교 산학협력단 | 당 부가 아미노글리코사이드 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물 |
| CN105461650B (zh) * | 2014-09-12 | 2018-04-13 | 杭州普晒医药科技有限公司 | 一种噁二唑化合物的溶剂化物及其制备方法 |
| CU24509B1 (es) | 2015-03-10 | 2021-05-12 | Aurigene Discovery Tech Ltd | Compuestos de 1,2,4-oxadiazol y tiadiazol como inmunomoduladores |
| CA2980801A1 (en) | 2015-04-24 | 2016-10-27 | Omeros Corporation | Pde10 inhibitors and related compositions and methods |
| TW201729807A (zh) | 2015-10-30 | 2017-09-01 | Ｐｔｃ治療公司 | 用於治療癲癇的方法 |
| CA3003611C (en) | 2015-11-04 | 2022-11-01 | Omeros Corporation | Solid state forms of a pde10 inhibitor |
| EP3442512A4 (en) * | 2016-04-15 | 2020-07-22 | The UAB Research Foundation | METHODS AND COMPOUNDS FOR STIMULATING THE TRANSLECTURE OF PREMATURE TERMINATION CODONS |
| EP3512516A1 (en) * | 2016-09-13 | 2019-07-24 | Marco Cipolli | Method of treatment of shwachman-diamond syndrome |
| WO2019061324A1 (en) | 2017-09-29 | 2019-04-04 | Curis Inc. | CRYSTALLINE FORMS OF IMMUNOMODULATORS |
| KR20240151258A (ko) | 2017-10-11 | 2024-10-17 | 오리진 온콜로지 리미티드 | 3-치환된 1,2,4-옥사다이아졸의 결정질 형태 |
| EA202090746A1 (ru) | 2017-11-03 | 2020-08-17 | Ориджен Дискавери Текнолоджис Лимитед | Двойные ингибиторы путей tim-3 и pd-1 |
| CN111386128A (zh) | 2017-11-06 | 2020-07-07 | 奥瑞基尼探索技术有限公司 | 用于免疫调节的联合疗法 |
| MX2021012428A (es) | 2019-04-10 | 2022-01-19 | Ptc Therapeutics Inc | Metodo para el tratamiento de distrofia muscular de duchenne mediada por mutacion sin sentido en pacientes pediatricos. |
| JP7339900B2 (ja) * | 2020-02-26 | 2023-09-06 | 新 井上 | 視野異常診断方法、視野異常診断装置 |
| KR102665711B1 (ko) * | 2021-12-21 | 2024-05-14 | 재단법인 아산사회복지재단 | Ras 활성도를 이용한 신경섬유종증 치료제에 대한 감수성 예측용 바이오마커 조성물 및 Ras 활성 억제제를 포함하는 신경섬유종증 예방 또는 치료용 약학적 조성물 |
| WO2025110781A1 (ko) * | 2023-11-24 | 2025-05-30 | 재단법인 아산사회복지재단 | Ampd3를 포함하는 신경섬유종증 치료제에 대한 감수성 예측용 바이오마커 조성물 및 ampd3 저해제를 포함하는 신경섬유종증 예방 또는 치료용 약학 조성물 |
| CN118178408A (zh) * | 2024-03-22 | 2024-06-14 | 核工业总医院 | Ptc124在制备治疗血小板无力症的药物中的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW264475B (enExample) | 1991-09-20 | 1995-12-01 | Takeda Pharm Industry Co Ltd | |
| US6660753B2 (en) | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| CN1638776A (zh) | 2001-06-08 | 2005-07-13 | 西托维亚公司 | 取代的3－芳基－5－芳基－[1,2,4]－噁二唑和类似物 |
| MY151199A (en) | 2001-11-02 | 2014-04-30 | Rigel Pharmaceuticals Inc | Substituted diphenyl heterocycles useful for treating hcv infection |
| WO2004001010A2 (en) * | 2002-06-21 | 2003-12-31 | Ptc Therapeutics, Inc. | METHODS FOR IDENTIFYING SMALL MOLECULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY |
| US6889231B1 (en) * | 2002-08-01 | 2005-05-03 | Oracle International Corporation | Asynchronous information sharing system |
| TW200812986A (en) | 2002-08-09 | 2008-03-16 | Nps Pharma Inc | New compounds |
| GB0303503D0 (en) | 2003-02-14 | 2003-03-19 | Novartis Ag | Organic compounds |
| US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| DK3549936T3 (da) * | 2003-04-11 | 2021-07-12 | Ptc Therapeutics Inc | 1,2,4-oxadiazol-benzoesyreforbindelse og dens anvendelse til nonsense-undertrykkelse og behandlingen af sygdom |
| US20050075375A1 (en) | 2003-05-14 | 2005-04-07 | Anadys Pharmaceuticals, Inc. | Heterocyclic compounds for treating hepatitis C virus |
| EP2402323A3 (en) * | 2004-10-13 | 2012-05-30 | PTC Therapeutics, Inc. | Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases |
| EP1819340A2 (en) * | 2004-12-08 | 2007-08-22 | Biomarin Pharmaceutical Inc. | Methods and compositions for the treatment of pulmonary hypertension of the newborn |
| ES2683359T3 (es) | 2005-04-08 | 2018-09-26 | Ptc Therapeutics, Inc. | Composiciones que comprenden un 1,2,4-oxadiazol y usos de las mismas para tratar enfermedades asociadas con un codón de parada prematura |
| MX2009002439A (es) * | 2006-09-08 | 2009-03-27 | Ptc Therapeutics Inc | Procesos para la preparacion de acidos 1,2,4-oxadiazolbenzoicos. |
| PL2076501T3 (pl) * | 2006-09-25 | 2016-06-30 | Ptc Therapeutics Inc | Postacie krystaliczne kwasu 3-[5-(2-fluorofenylo)[1,2,4]oksadiazol-3-ilo]-benzoesowego |
| CA3174516A1 (en) * | 2014-03-06 | 2015-09-11 | Ptc Therapeutics, Inc. | Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid |
-
2007
- 2007-09-24 PL PL07838770T patent/PL2076501T3/pl unknown
- 2007-09-24 PL PL12185448T patent/PL2559689T3/pl unknown
- 2007-09-24 WO PCT/US2007/020633 patent/WO2008039431A2/en not_active Ceased
- 2007-09-24 EP EP07838770.1A patent/EP2076501B8/en active Active
- 2007-09-24 NZ NZ575795A patent/NZ575795A/en unknown
- 2007-09-24 HU HUE07838770A patent/HUE028503T2/en unknown
- 2007-09-24 BR BRPI0717107-2A patent/BRPI0717107A2/pt not_active Application Discontinuation
- 2007-09-24 KR KR1020097008202A patent/KR101430144B1/ko active Active
- 2007-09-24 DK DK07838770.1T patent/DK2076501T3/da active
- 2007-09-24 SG SG2012082715A patent/SG185979A1/en unknown
- 2007-09-24 CN CN201110283329.XA patent/CN102382075B/zh active Active
- 2007-09-24 CA CA2663574A patent/CA2663574C/en active Active
- 2007-09-24 ES ES12185448.3T patent/ES2655338T3/es active Active
- 2007-09-24 MX MX2011007120A patent/MX344418B/es unknown
- 2007-09-24 AU AU2007300542A patent/AU2007300542B2/en active Active
- 2007-09-24 US US11/904,005 patent/US7863456B2/en active Active
- 2007-09-24 SI SI200731750A patent/SI2076501T1/sl unknown
- 2007-09-24 CN CNA200780043582XA patent/CN101541770A/zh active Pending
- 2007-09-24 CL CL200702743A patent/CL2007002743A1/es unknown
- 2007-09-24 ZA ZA200901949A patent/ZA200901949B/xx unknown
- 2007-09-24 ES ES07838770.1T patent/ES2563958T3/es active Active
- 2007-09-24 MX MX2009003160A patent/MX2009003160A/es active IP Right Grant
- 2007-09-24 EP EP12185448.3A patent/EP2559689B1/en active Active
- 2007-09-24 UA UAA200904012A patent/UA99600C2/ru unknown
- 2007-09-24 JP JP2009529270A patent/JP5714228B2/ja active Active
- 2007-09-24 CN CN201410561812.3A patent/CN104341371A/zh active Pending
- 2007-09-24 PT PT78387701T patent/PT2076501E/pt unknown
- 2007-09-24 MY MYPI20091186A patent/MY191209A/en unknown
- 2007-09-24 AR ARP070104212A patent/AR062963A1/es not_active Application Discontinuation
- 2007-09-24 SG SG10201609581TA patent/SG10201609581TA/en unknown
- 2007-09-25 PE PE2011001746A patent/PE20120768A1/es not_active Application Discontinuation
- 2007-09-25 PE PE2007001290A patent/PE20081225A1/es not_active Application Discontinuation
- 2007-09-25 PE PE2015001242A patent/PE20151445A1/es not_active Application Discontinuation
- 2007-09-26 TW TW096135785A patent/TWI452038B/zh active
- 2007-09-26 TW TW103104823A patent/TWI496775B/zh active
-
2009
- 2009-03-19 IL IL197717A patent/IL197717A/en active IP Right Grant
- 2009-04-16 NO NO20091488A patent/NO341858B1/no unknown
-
2010
- 2010-10-27 US US12/913,213 patent/US8394966B2/en active Active
-
2013
- 2013-02-12 US US13/764,807 patent/US8748625B2/en active Active
-
2014
- 2014-04-25 US US14/261,774 patent/US9309206B2/en active Active
-
2015
- 2015-01-09 JP JP2015003265A patent/JP6407733B2/ja active Active
- 2015-08-10 HK HK15107681.2A patent/HK1207070A1/xx unknown
-
2016
- 2016-03-14 US US15/068,792 patent/US10028939B2/en active Active
- 2016-04-22 LT LTPA2016012C patent/LTC2076501I2/lt unknown
-
2017
- 2017-05-29 JP JP2017106030A patent/JP6495375B2/ja active Active
- 2017-08-07 AR ARP170102217A patent/AR109300A2/es unknown
-
2018
- 2018-06-22 US US16/015,389 patent/US10300047B2/en active Active
-
2019
- 2019-03-06 JP JP2019040137A patent/JP2019104752A/ja not_active Withdrawn
- 2019-04-10 US US16/380,218 patent/US10959988B2/en not_active Expired - Fee Related
-
2020
- 2020-07-07 US US16/921,934 patent/US20200330440A1/en not_active Abandoned
-
2021
- 2021-02-24 US US17/183,342 patent/US20210330647A1/en not_active Abandoned
- 2021-05-31 JP JP2021090763A patent/JP7245868B2/ja active Active
- 2021-09-30 US US17/490,725 patent/US20220023268A1/en not_active Abandoned
-
2023
- 2023-03-13 JP JP2023038770A patent/JP2023078271A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2076501T3 (da) | Krystallinske former af 3-[5-(2-fluorphenyl)-[1,2,4]oxadiazol-3-yl]-benzoesyre | |
| DK3040333T3 (da) | Krystallinske former af 5-(2,6-di-4-morpholinyl-4-pyridmidinyl)-4-trifluormethylpyridin-2-amin, en pik3-hæmmer | |
| ZA200802488B (en) | 1-heterocyclylsulfonyl, 2-aminomethyl, 5- (hetero-) aryl substituted 1-h-pyrrole derivatives as acid secretion inhibitors | |
| RU2465270C3 (ru) | Полиморфная форма 4-[3-(4-циклопропанкарбонилпиперазин-1-карбонил)-4-фторбензил]-2н-фталазин-1-она | |
| EP2473504A4 (en) | HETEROCYCLIC COMPOUNDS FOR PASK INHIBITION | |
| DK2021335T3 (da) | Heterocykliske forbindelser som C-FMS-kinasehæmmere | |
| DK2117297T3 (da) | Krystallinske komplekser af landbrugsmæssigt aktive organiske forbindelser | |
| IL207854A0 (en) | Crystal forms of 5-[3-(2,5-dichloro-4, 6-dimethyl-1-oxy-pyridine-3-yl)[1,2,4]oxadiazol-5-yl]-3-nit robenzene-1,2-diol | |
| HUE045138T2 (hu) | 4-[5-(Piridin-4-il)-1H-1,2,4-triazol-3-il]piridin-2-karbonitril kristályos formája | |
| IL180358A0 (en) | Crystalline form iv of linezolid | |
| IL183380A0 (en) | Crystalline forms of linezolid intermediate | |
| SI2132204T1 (sl) | Kristalinične oblike 8-azabiciklo(3.2.1) oktanske spojine | |
| EA201071299A1 (ru) | 5-[5-[2-(3,5-бис(трифторметил)фенил)-2-метилпропаноилметиламино]-4-(4-фтор-2-метилфенил)]-2-пиридинил-2-алкилпролинамиды в качестве антагонистов рецептора nk1 | |
| NO20075383A (no) | Regulering av tyngre maskiner | |
| PL2722046T3 (pl) | Postać krystaliczna 1 2-((R)-2-metylopirolidyn-2-ylo)-1H-benzoimidazolo-4-karboksyamidu | |
| ECSP099344A (es) | Modificaciones de cristal de la 3-(1h-indol-3-il)-4-[2-(4-metil-piperazin-1-il)-quinazolin-4-il]-pirrol-2,5-diona | |
| ITMI20042437A1 (it) | Forma cristallina di rabeprazolo sodico | |
| DK2220082T3 (da) | Stabilt krystallinsk salt af (R)-3-fluorphenyl-3,4,5-trifluorbenzylcarbaminsyre-1-azabicyclo[2.2.2]oct-3-ylester | |
| DK2222376T3 (da) | 3-(2,2,2-trimethylhydrazinium)propionatsalte til behandling af myokardieinfarkt | |
| DE602006020998D1 (de) | Monolysinsalze von azolverbindungen | |
| NO20091862L (no) | N-(3-bensyl) -2, 2- (bis-fenyl) - propan-1-amin derivativer som CETP inhibitorer for behandlingen av atherosclerose and cardiovaskulaere sykdommer | |
| CY1113938T1 (el) | Διαδικασιες για την παρασκευη 1,2,4-οξαδιαζολο βενζοϊκων οξεων | |
| WO2008138754A3 (en) | New solid forms of fxa inhibitors | |
| SE0700083L (sv) | Nya kristallina former 2 | |
| UA11341U (uk) | Морфолінієва сіль 5-(3-піридил)-1,2,4-триазол-3-ілтіоацетатної кислоти, яка має упереджувальну дію щодо набряку мозку, викликаного широкосмуговою вібрацією |